GO:0004953 icosanoid receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004953 (icosanoid receptor activity) is a molecular function defined as combining with an icosanoid to initiate a change in cell activity.
• Icosanoids include prostaglandins, thromboxanes, leukotrienes, lipoxins, and endocannabinoids, which act as local lipid mediators.
• Receptors for icosanoids include G-protein-coupled receptors (GPCRs) such as cannabinoid receptors CB1 and CB2, and prostanoid receptors.
• Icosanoid receptor signaling is implicated in platelet reactivity, vascular tone, pulmonary arterial hypertension, cancer progression, and neuroendocrine regulation.
• Experimental models for studying icosanoid receptor activity include knockout mice, point-mutation knock-in models, and overexpression cell lines.
• CRISPR-based knockout, knock-in, and overexpression platforms enable precise interrogation of icosanoid receptor function in disease contexts.
Description
Icosanoid receptor activity (GO:0004953) is a molecular function that enables a cell to respond to icosanoids, a family of oxygenated lipid mediators derived from arachidonic acid and related fatty acids. These receptors are critical for translating local lipid signals into diverse cellular responses, including platelet activation, vascular remodeling, and inflammation. The term encompasses receptors that bind prostaglandins, thromboxanes, leukotrienes, lipoxins, and endocannabinoids, thereby initiating intracellular signaling cascades. Researchers study icosanoid receptor activity to understand how lipid mediators control physiology and disease. For example, cannabinoid receptors CB1 and CB2 are icosanoid receptors that mediate the effects of endocannabinoids and synthetic cannabinoids. In the vasculature, transcellular signaling involving icosanoids regulates platelet-vessel wall interactions. Dysregulated icosanoid receptor activity has been linked to pulmonary arterial hypertension, cancer, and metabolic disorders. This article provides a research-grade overview of GO:0004953, covering its definition, mechanism, key genes, disease relevance, and experimental methods, with a focus on CRISPR-based models for functional studies.
icosanoid receptor activity At A Glance
| GO ID | GO:0004953 |
|---|---|
| GO term | icosanoid receptor activity |
| Ontology | molecular_function |
| Synonym | eicosanoid receptor activity |
| Definition | Combining with an icosanoid to initiate a change in cell activity. |
| Major function | Binding of icosanoid lipid mediators to initiate intracellular signaling. |
| Representative receptors | Cannabinoid receptors CB1 (CNR1) and CB2 (CNR2), prostanoid receptors, leukotriene receptors. |
| Associated processes | Platelet activation, vascular tone regulation, inflammation, neurotransmission. |
| Disease relevance | Pulmonary arterial hypertension, cancer, metabolic and neuroendocrine disorders. |
What Is GO:0004953?
According to the Gene Ontology, icosanoid receptor activity (GO:0004953) is the molecular function of combining with an icosanoid to initiate a change in cell activity. In other words, it is the ability of a receptor protein to bind an icosanoid lipid mediator and trigger downstream signaling events that alter cellular behavior.
Why Is icosanoid receptor activity Important in Cell Biology?
Icosanoid receptor activity is essential for converting lipid signals into physiological responses. It plays a central role in platelet reactivity, vascular homeostasis, and inflammation, and is a target for drugs used in pulmonary arterial hypertension and other diseases. Understanding this activity at the molecular level can reveal new therapeutic strategies and biomarkers.
• Mediates the cellular effects of prostaglandins, thromboxanes, leukotrienes, and endocannabinoids.
• Regulates platelet activation and thrombus formation through 12-lipoxygenase-dependent pathways.
• Influences vascular tone and remodeling, with implications for pulmonary arterial hypertension.
• Modulates cancer cell proliferation and survival via eicosanoid signaling.
• Participates in neuroendocrine and nutritional regulation through endocannabinoid receptors.
• Provides targets for therapeutic intervention, such as riociguat and treprostinil in PAH.
• Enables transcellular signaling between platelets, endothelial cells, and leukocytes.
• Is a focus for CRISPR-based functional genomics to dissect receptor-specific contributions.
Mechanism, Genes and Research Methods
Ligand Binding and Receptor Activation
In simple terms: An icosanoid molecule binds to its receptor, like a key in a lock, turning the receptor on.
Icosanoid receptors are typically G-protein-coupled receptors (GPCRs) that bind specific lipid ligands. For example, cannabinoid receptors CB1 and CB2 bind endocannabinoids and synthetic cannabinoids, initiating intracellular signaling. Prostanoid receptors bind prostaglandins and thromboxanes, while leukotriene receptors bind leukotrienes. This binding event is the first step in icosanoid receptor activity.
G-Protein Coupling and Second Messenger Generation
In simple terms: Once activated, the receptor activates G-proteins, which then trigger second messengers inside the cell.
Upon ligand binding, icosanoid receptors couple to heterotrimeric G-proteins, leading to activation or inhibition of enzymes such as adenylyl cyclase or phospholipase C. This results in changes in cyclic AMP, calcium, or other second messengers. Cannabinoid receptors, for instance, are known to modulate adenylyl cyclase and ion channels. These signaling events mediate the cellular response to icosanoids.
Downstream Signaling and Cellular Responses
In simple terms: The second messengers activate various proteins that change how the cell behaves.
Downstream effectors include protein kinases, ion channels, and transcription factors. In platelets, 12-lipoxygenase activity and icosanoid receptor signaling contribute to PAR4- and GPVI-mediated platelet reactivity. In cancer, eicosanoids and their receptors influence HB-EGF/EGFR signaling pathways. These responses can alter cell shape, movement, proliferation, and survival.
Transcellular Biosynthesis and Signaling
In simple terms: Different cell types cooperate to produce and respond to icosanoids, allowing complex signaling networks.
Icosanoids can be synthesized by one cell type and act on neighboring cells, a process known as transcellular signaling. This is important in vascular biology, where platelet-endothelial interactions generate icosanoids that modulate thrombosis and inflammation. Such intercellular communication amplifies and diversifies the effects of icosanoid receptor activity.
Regulation of Receptor Expression and Desensitization
In simple terms: Cells can adjust how many receptors they have and how strongly they respond, preventing overstimulation.
Icosanoid receptor activity is regulated at multiple levels, including receptor expression, post-translational modifications, and desensitization. Prolonged agonist exposure can lead to receptor internalization and downregulation. Endocannabinoid signaling is also influenced by nutritional status, as shown by studies on endocannabinoids and nutrition. These regulatory mechanisms ensure appropriate responses to lipid mediators.
Key Genes Involved in GO:0004953 icosanoid receptor activity
The following genes encode receptors and enzymes directly involved in icosanoid receptor activity and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CNR1 | Cannabinoid receptor 1, binds endocannabinoids | Mediates psychoactive and metabolic effects of cannabinoids |
| CNR2 | Cannabinoid receptor 2, binds endocannabinoids | Regulates immune and inflammatory responses |
| PTGS1 | Cyclooxygenase-1, synthesizes prostaglandins | Produces ligands for prostanoid receptors |
| PTGS2 | Cyclooxygenase-2, inducible prostaglandin synthesis | Inflammation and cancer-related eicosanoid production |
| ALOX12 | 12-lipoxygenase, produces 12-HETE | Platelet reactivity and icosanoid signaling |
| ALOX5 | 5-lipoxygenase, produces leukotrienes | Leukotriene receptor ligand synthesis |
| PTGER1 | Prostaglandin E receptor 1 | Mediates PGE2 effects in various tissues |
| PTGER2 | Prostaglandin E receptor 2 | Regulates inflammation and cancer |
| PTGER4 | Prostaglandin E receptor 4 | Immune modulation and cancer progression |
| TBXA2R | Thromboxane A2 receptor | Vascular tone and platelet aggregation |
| LTB4R | Leukotriene B4 receptor | Inflammation and chemotaxis |
| CysLT1 | Cysteinyl leukotriene receptor 1 | Asthma and allergic responses |
| CysLT2 | Cysteinyl leukotriene receptor 2 | Vascular and inflammatory signaling |
| GPR55 | Putative cannabinoid receptor | Lipid signaling and immune function |
| PPARG | Peroxisome proliferator-activated receptor gamma | Binds eicosanoids and regulates metabolism |
| FAAH | Fatty acid amide hydrolase, degrades endocannabinoids | Regulates endocannabinoid tone |
| MGLL | Monoacylglycerol lipase, degrades 2-AG | Endocannabinoid signaling regulation |
How Is icosanoid receptor activity Regulated?
Icosanoid receptor activity is regulated by ligand availability, receptor expression levels, and desensitization mechanisms. Endocannabinoid signaling is influenced by nutritional status and metabolic state. In platelets, 12-lipoxygenase activity modulates PAR4 and GPVI-mediated reactivity, indicating that upstream enzymes regulate receptor responses. Additionally, transcellular biosynthesis can control the local concentration of icosanoids available to activate receptors.
icosanoid receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNR1 | Metabolic syndrome, neuropsychiatric disorders | Knockout mouse, point-mutation knock-in |
| PTGS2 | Cancer, inflammation | Overexpression cell line, knockout |
| ALOX12 | Platelet reactivity, thrombosis | Knockout mouse, point-mutation |
| TBXA2R | Pulmonary arterial hypertension | Knock-in mouse, overexpression |
| LTB4R | Inflammatory diseases | Knockout mouse, CRISPR library screening |
Pulmonary Arterial Hypertension
Icosanoid receptor signaling is involved in pulmonary arterial hypertension (PAH). Drugs such as riociguat and treprostinil, which act on pathways related to icosanoid signaling, are used to treat PAH. These therapies highlight the importance of icosanoid receptor activity in vascular remodeling and tone.
Cancer
Eicosanoids and their receptors promote cancer progression by stimulating proliferation, angiogenesis, and survival. The interplay between eicosanoids and HB-EGF/EGFR signaling is a key mechanism in cancer. Targeting icosanoid receptors may offer therapeutic opportunities.
Platelet Disorders and Thrombosis
12-lipoxygenase activity and icosanoid receptor signaling contribute to platelet reactivity, influencing thrombus formation. Dysregulation can lead to bleeding or thrombotic disorders.
Metabolic and Neuroendocrine Disorders
Endocannabinoids and their receptors are involved in nutrition and metabolic regulation. Cannabinoid receptor signaling also affects neuroendocrine functions, with implications for obesity and metabolic syndrome.
From icosanoid receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of receptor X affect ligand-induced signaling? | Knockout cell line or mouse |
| Does a specific point mutation alter ligand binding affinity? | Point-mutation knock-in |
| Can a tagged receptor be used to track localization? | Tagged knock-in |
| Does overexpression of receptor Y drive proliferation? | Overexpression cell line |
| Which genes modulate receptor sensitivity? | CRISPR library screening |
| How does receptor activation change gene expression? | RNA-seq after receptor stimulation |
How to Study the icosanoid receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor-ligand affinity | Characterize receptor pharmacology |
| cAMP assay | G-protein coupling | Measure receptor activation |
| Calcium imaging | Intracellular calcium flux | Assess GPCR signaling |
| CRISPR knockout | Loss of gene function | Determine receptor necessity |
| CRISPR knock-in | Introduction of specific mutations | Study structure-function relationships |
| RNA-seq | Global gene expression changes | Identify downstream pathways |
| Proteomics | Protein expression and modifications | Map signaling networks |
Ligand Binding Assays
Radioligand binding or fluorescent ligand binding assays measure the affinity and specificity of icosanoid receptors for their ligands. These assays are fundamental for characterizing receptor activity.
Signal Transduction Assays
Second messenger measurements, such as cAMP or calcium mobilization, are used to assess receptor activation. For example, cannabinoid receptor signaling can be monitored by changes in cAMP levels.
Genetic Knockout and Knock-in Models
CRISPR-Cas9 technology enables the generation of knockout and knock-in cell lines and animal models to study the loss- or gain-of-function of specific icosanoid receptors.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can reveal downstream changes in gene expression and protein networks following receptor activation or genetic manipulation.
How CRISPR Can Be Used to Study GO:0004953 icosanoid receptor activity
Knockout
CRISPR knockout of icosanoid receptor genes, such as CNR1 or PTGER2, can abolish receptor activity and reveal its role in cellular responses. This approach is useful for validating drug targets and understanding disease mechanisms.
Point Mutation
Point mutations can be introduced to study specific amino acid residues involved in ligand binding or G-protein coupling. For example, mutating key residues in the cannabinoid receptor can alter its signaling properties.
Knock-in
Knock-in of tagged or reporter versions of icosanoid receptors allows real-time tracking of receptor localization and dynamics. This can be combined with live-cell imaging to study receptor trafficking.
Overexpression
Overexpression of icosanoid receptors in cell lines can enhance signaling and is used to study gain-of-function effects, such as increased proliferation in cancer models.
How EDITGENE Supports icosanoid receptor activity Research
Researchers studying icosanoid receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of icosanoid receptors and their regulators.
Contact EDITGENE today to design your custom CRISPR model for icosanoid receptor activity research.
Frequently Asked Questions About icosanoid receptor activity
What is icosanoid receptor activity?
Icosanoid receptor activity (GO:0004953) is a molecular function where a receptor binds an icosanoid lipid mediator and initiates a change in cell activity.
What genes are involved in icosanoid receptor activity?
Key genes include CNR1, CNR2, PTGS1, PTGS2, ALOX12, ALOX5, PTGER1-4, TBXA2R, LTB4R, and CysLT1/2, among others.
What are icosanoids?
Icosanoids are oxygenated lipid mediators derived from arachidonic acid, including prostaglandins, thromboxanes, leukotrienes, and endocannabinoids.
How is icosanoid receptor activity studied?
It is studied using ligand binding assays, signal transduction assays, CRISPR knockout/knock-in models, and transcriptomic profiling.
What diseases are associated with icosanoid receptor activity?
Diseases include pulmonary arterial hypertension, cancer, thrombosis, and metabolic disorders.
What is the role of cannabinoid receptors in icosanoid signaling?
Cannabinoid receptors CB1 and CB2 bind endocannabinoids and mediate various physiological effects, including neuroendocrine and immune regulation.
Can CRISPR be used to study icosanoid receptors?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect receptor function and signaling.
What are the synonyms for icosanoid receptor activity?
The synonym is eicosanoid receptor activity.
Which GO term describes icosanoid receptor activity?
GO:0004953 is the Gene Ontology term for icosanoid receptor activity.
How does icosanoid receptor activity relate to cancer?
Eicosanoid receptors can promote cancer cell proliferation and survival, often through cross-talk with EGFR signaling.
Conclusion
Icosanoid receptor activity (GO:0004953) is a fundamental molecular function that translates lipid signals into diverse cellular responses. Its roles in platelet function, vascular biology, cancer, and metabolism make it a critical area of research. Understanding the mechanisms and regulation of icosanoid receptors can lead to new therapeutic approaches for related diseases. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, are invaluable for dissecting the specific contributions of individual receptors and their downstream pathways. EDITGENE provides comprehensive services to support these studies, from custom cell line generation to library screening and bioinformatics analysis.
References
- 1. Ghofrani HA et al.. 2013. Riociguat for the treatment of pulmonary arterial hypertension.. N Engl J Med 369(4):330-40 PMID: 23883378
- 2. Yeung J et al.. 2013. 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity.. Thromb Haemost 110(3):569-81 PMID: 23784669
- 3. Howlett AC. 2002. The cannabinoid receptors.. Prostaglandins Other Lipid Mediat 68-69:619-31 PMID: 12432948
- 4. Marcus AJ et al.. 1993. Vascular transcellular signaling.. J Lipid Res 34(12):2017-31 PMID: 8301223
- 5. Yang CC et al.. 2018. Eicosanoids and HB-EGF/EGFR in cancer.. Cancer Metastasis Rev 37(2-3):385-395 PMID: 29936588
- 6. Burstein SH. 2019. Eicosanoid mediation of cannabinoid actions.. Bioorg Med Chem 27(13):2718-2728 PMID: 31104784
- 7. Tapson VF et al.. 2012. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.. Chest 142(6):1383-1390 PMID: 22628490
- 8. Hansen HS et al.. 2008. Endocannabinoids and nutrition.. J Neuroendocrinol 20 Suppl 1:94-9 PMID: 18426507
